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The significance of the inter-relationship between tumour and host local/systemic inflammatory responses in primary operable
invasive breast cancer is limited. The inter-relationship between the systemic inflammatory response (pre-operative white cell count,
C-reactive protein and albumin concentrations), standard clinicopathological factors, tumour T-lymphocytic (CD4þ and CD8þ)
and macrophage (CD68þ) infiltration, proliferative (Ki-67) index and microvessel density (CD34þ) was examined using
immunohistochemistry and slide-counting techniques, and their prognostic values were examined in 168 patients with potentially
curative resection of early-stage invasive breast cancer. Increased tumour grade and proliferative activity were associated with greater
tumour T-lymphocyte (Po0.05) and macrophage (Po0.05) infiltration and microvessel density (Po0.01). The median follow-up of
survivors was 72 months. During this period, 31 patients died; 18 died of their cancer. On univariate analysis, increased lymph-node
involvement (Po0.01), negative hormonal receptor (Po0.10), lower albumin concentrations (Po0.01), increased tumour
proliferation (Po0.05), increased tumour microvessel density (Po0.05), the extent of locoregional control (Po0.0001) and limited
systemic treatment (Pp0.01) were associated with cancer-specific survival. On multivariate analysis of these significant covariates,
albumin (HR 4.77, 95% CI 1.35–16.85, P¼0.015), locoregional treatment (HR 3.64, 95% CI 1.04–12.72, P¼0.043) and systemic
treatment (HR 2.29, 95% CI 1.23–4.27, P¼0.009) were significant independent predictors of cancer-specific survival. Among
tumour-based inflammatory factors, only tumour microvessel density (Po0.05) was independently associated with poorer cancer-
specific survival. The host inflammatory responses are closely associated with poor tumour differentiation, proliferation and malignant
disease progression in breast cancer.
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It is now recognised that the development of cancer and its
progression is dependent on a complex interaction of the tumour
and the host inflammatory response (Coussens and Werb, 2002;
Vakkila and Lotze, 2004). Recently, the systemic inflammatory
response, as evidenced by elevated circulating concentrations of
C-reactive protein and hypoalbuminaemia, has been shown to be
independently associated with poorer survival in patients with
advanced disease (McMillan et al, 2001; Forrest et al, 2003)
including breast cancer (Albuquerque et al, 1995; Zhang and
Adachi, 1999; Al Murri et al, 2006). There is also some evidence
that these acute-phase proteins have independent prognostic value
in primary operable disease (McMillan et al, 2003, 2007) including
breast cancer (Lis et al, 2003; Al Murri et al, 2007).
In animal models, at least, it would appear that the cell-mediated
immune response is more important than humoural immunity in
preventing the progression of cancer, and there is some evidence
that cell-mediated immunity can bring about tumour regression.
The principal cells involved in the cell-mediated response are
T lymphocytes and macrophages (O’Sullivan and Lewis, 1994; Lee
et al, 1996, 2006; Ogmundsdottir, 2001). However, this immune
response, in particular the local environment of cytokines,
proteases, angiogenic/growth factors and the resulting systemic
inflammatory response, may, in turn, stimulate tumour growth
and metastasis (O’Sullivan and Lewis, 1994; Leek et al, 1996;
Yu and Rak, 2003; Lin and Pollard, 2007).
A number of studies have observed that, in breast tumours,
there is a diffuse infiltrate of T lymphocytes and macrophages (Lee
et al, 1996, 2006). It is also observed that there is an association
with better outcome in patients with a moderate or marked diffuse
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sinflammatory pattern in the subgroup of high-grade cases (Pupa
et al, 1996; Lee et al, 2006). Recently, the use of immunohisto-
chemical techniques to reliably identify and assess tumour-
infiltrating T lymphocyte subsets and macrophages has led to
renewed interest in the relationship between the tumour inflamma-
tory infiltrate and cancer-specific survival in a variety of common
solid tumours. With reference to tumour T-lymphocytic infiltration,
a significant association with survival has been shown in renal
(Bromwich et al, 2003), prostate (McArdle et al,2 0 0 4 ) ,c o l o r e c t a l
(Canna et al, 2005; Galon et al, 2006) and head and neck cancers
(Badoual et al, 2006). However, few studies have examined the
association between tumour CD4þ/CD8þ T-lymphocytic infiltra-
tion and/or CD68þ macrophage infiltration and survival in patients
with primary operable breast cancer (Griffith et al, 1990; Wintzer
et al, 1991; Leek et al, 1996; Toi et al, 1999; Tsutsui et al, 2005).
Griffith et al (1990) and Wintzer et al (1991) have both reported
that disease-free survival and overall survival in breast cancer
patients were not influenced by the tumour infiltration of any
lymphocyte subset. However, these were relatively small studies of
less than 80 patients. In contrast, different monocyte subsets
appeared to be associated with either good or poor disease-free
survival (Toi et al, 1999). Furthermore, in studies between 100 and
250 cases, there was conflicting evidence as to whether or not
CD68þ macrophage infiltration was superior to microvessel
density in predicting disease-free survival (Griffith et al, 1990;
Wintzer et al, 1991; Toi et al, 1999; Tsutsui et al, 2005).
Therefore, the inter-relationship between local and systemic
inflammatory responses and its prognostic significance in patients
with primary operable breast cancer remains unclear. The aim of
this study was to examine the relationship between circulating
concentrations of C-reactive protein and albumin, tumour
infiltration of T-lymphocyte sub-populations and macrophages
and survival in patients who had undergone potentially curative
surgical resection for invasive primary operable breast cancer.
PATIENTS AND METHODS
Patients with histologically proven invasive primary operable
breast cancer presenting consecutively to two hospitals (Western
Infirmary, Glasgow and Wishaw General Hospital, Lanarkshire) in
the west of Scotland between June 2001 and December 2002 and
who had a pre-operative measurement of C-reactive protein and
albumin (n¼168) were studied prospectively.
Clinicopathological data included the age, deprivation category,
histological type, tumour size, grade, lymph node status and
oestrogen and progesterone receptor status. The type of surgery
and the use of adjuvant treatment (chemotherapy, hormonal
therapy and radiotherapy) were recorded.
The extent of deprivation was derived from the 1991 census,
using the post-code of residence at diagnosis (Carstairs and
Morris, 1991). The results are presented by amalgamating the
seven categories into three groups: affluent (categories 1 and 2),
intermediate (categories 3–5) and deprived (categories 6 and 7).
Routine pre-operative laboratory measurement of C-reactive
protein, albumin and white cell count was carried out. At this
time, no patient showed clinical evidence of infection or other
inflammatory conditions. The coefficient of variation for these
measurements was less than 10% as established by routine quality
control procedures. The limit of detection of C-reactive protein
concentration assay was 6mgl
 1, with the upper limit of normal
values being p10mgl
 1.
The study was approved by the local research ethics committees.
Methods
Blocks from the primary tumour were fixed in 10% buffered
formalin in saline and embedded in paraffin wax. One representative
block of tumour was selected for each patient. Serial individual
sections (4mm) were cut and mounted on slides coated with
aminopropyltriethoxysilane for the immunohistochemistry of
Ki-67 (proliferative index), CD34þ (microvessel density),
CD68þ (tumour-associated macrophages) and CD4þ and
CD8þ (T lymphocytes).
Immunohistochemistry
Appropriate positive controls were included in each run. Negative
controls were omission of the primary antibody.
Ki-67 Sections were immunostained using the peroxidase-based
Envision technique (Dako, Cambridgeshire, UK) as described
earlier (McNicol et al, 1997). The primary antibody for Ki-67 was
mouse monoclonal antibody (Dako) at a dilution of 1:500.
CD34þ Sections were immunostained using the peroxidase-
based Envision technique (Dako). The primary antibody for
CD34þ was mouse monoclonal antibody (Novocastra, Newcastle
upon Tyne, UK) at a dilution of 1:50.
CD68þ Sections were immunostained using the peroxidase-
based Envision technique (Dako). The primary antibody for
CD68þ was mouse monoclonal antibody (Dako) at a dilution of
1:200.
CD4þ and CD8þ T lymphocytes Sections were immunostained
using the peroxidase-based Envision technique (Dako) as described
earlier (Bromwich et al, 2003). The primary antibody for CD4þ
was mouse monoclonal antibody (Vector, Peterborough, UK) at
a dilution of 1:10 and that for CD8þ was mouse mono-
clonal antibody (Dako) at a dilution of 1:1000.
Morphometry
Ki-67 The percentages of Ki-67-reactive tumour cells were evalu-
ated at a magnification of  400 (Figure 1) by scoring a minimum
of 1000 tumour cells in randomly selected fields (Ki-67 labelling
index).
CD34þ Quantitative analysis of the microvessel density was
performed by selecting the three most vascular areas (hot spots),
where the highest numbers of discrete microvessels were stained,
at low powers ( 40 and  100; Figure 2). Counting of discrete
vessels was performed with a magnification of  200, using a
25-point Chalkley grid as described by Hansen et al (2000a,b).
Figure 1 Ki67 immunohistochemical staining in invasive breast cancer
( 200).
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sCD68þ, CD4þ and CD8þ Quantitative analysis of the tumour-
associated macrophages (CD68þ; Figure 3) and lymphoid
infiltrates (CD4þ; Figure 4 and CD8þ; Figure 5) was performed
using a point counting method (Anderson and Dunnill, 1965) with
a random sampling technique. With this method, the volume
occupied by any given component (volume density) is expressed as
a percentage of the total volume of the tissue. A 100-point ocular
grid was used at a magnification of  400 and 30 fields were
counted per case for CD68þ, CD4þ and CD8þ immunopositive
cells.
Only fields containing tumour (including tumour nest and
surrounding tissues stroma) were counted. Any normal tissue on
the slide was excluded from the analysis. All the cases were
counted by the author AMAM. For the purpose of assessing inter-
observer reproducibility, a second observer (MH) and JB inde-
pendently scored the slides for the tumour microvessel density
(CD34þ) and tumour-associated macrophages (CD68þ), and
T lymphocytes (CD4þ and CD8þ) respectively. The observers
were blinded to the clinical outcome of the patient.
Statistics
Data are presented as median and range. Grouping of the
laboratory variables was carried out using standard thresholds
(Goldwasser and Feldman, 1997; McMillan et al, 2001). For the
purpose of analysis, the tumour Ki67 proliferative index, tumour-
associated macrophages (CD68þ) and T lymphocyte subset
populations (CD4þ and CD8þ) were grouped by tertiles, and
microvessel density (CD34þ) was grouped by vascular grade
based on Chalkley mean count with cutoff points at 5 and 7 as
described by Hansen et al (2000a,b). The relationships between
these and other variables were analysed using the Mantel–
Haenszel (w
2) test for trend and Spearman rank correlation as
appropriate.
Survival analysis was performed using the Cox proportional
hazard model. Multivariate survival analysis was performed using
stepwise backward procedure to derive a final model of the
variables that had a significant independent relationship with
survival. To remove a variable from the model, the corresponding
P-value had to be a greater than 0.10. Deaths up to the end of
March 2008 were included in the analysis. Analysis was performed
using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The baseline clinicopathological characteristics of the patients with
primary operable breast cancer (n¼168) are shown in Table 1.
One hundred and thirty-six (81%) patients were over 50 years of
age, and 49 (29%) were in the most deprived categories 6 and 7.
Of the 168 patients, 142 (85%) patients had ductal carcinoma,
100 (60%) had a tumour less than 2cm and 139 (83%) had a grade
Figure 3 CD68þ immunohistochemical staining in invasive breast
cancer ( 400).
Figure 4 CD4þ immunohistochemical staining in invasive breast cancer
( 400).
Figure 5 CD8þ immunohistochemical staining in invasive breast cancer
( 400).
Figure 2 CD34þ immunohistochemical staining in invasive breast
cancer ( 200).
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sII/III tumour. Ninety-four (56%) patients had no axillary lymph
node involvement. Thirty-five patients (21%) had oestrogen
receptor-negative tumours.
Before surgery, the majority had white cell count, albumin and
C-reactive protein concentrations in the normal range (96, 100 and
85% respectively). C-reactive protein concentration was correlated
with albumin concentration (rs¼ 0.24, P¼0.003) but not white
cell count (rs¼0.13, P¼0.100).
In all, 162 (97%) patients received adjuvant treatment in the
form of endocrine therapy and/or chemotherapy.
The inter-relationships between clinicopathological charac-
teristics are shown in Table 2. In all patients, high tumour grade
was positively associated with negative hormonal receptor status
(Po0.001), high Ki-67 labelling index (Po0.001) and high expres-
sion of CD34þ (Po0.01), CD68þ (Po0.05), CD4þ (Po0.05)
and CD8þ (Po0.05) T lymphocytes. Similarly, Ki-67 labelling
index was positively associated with CD34þ (Po0.001), CD68þ
(Pp0.001), CD4þ (Po0.001) and CD8þ (Po0.01) T lympho-
cytes. Negative hormonal receptor tumours were positively
associated with lower albumin concentration (Po0.05), high
Ki-67 labelling index (Po0.001) and the presence of CD68þ
(Po0.05) and CD8þ (Po0.05) T lymphocytes. An elevated
C-reactive protein concentration was positively associated with
the expression of CD34þ (P¼0.05) and the presence of CD4þ
T lymphocytes (Po0.05).
Microvessel density CD34þ was positively associated with the
presence of CD68þ (Po0.01) and CD4þ T lymphocytes
(Po0.05). Tumour-associated macrophages CD68þ were posi-
tively correlated with tumour CD4þ (Po0.01) and CD8þ
(Po0.001) T lymphocytes. Tumour CD4þ T lymphocytes were
also positively associated with CD8þ T lymphocytes (Po0.001).
The minimum follow-up was 64 months and the median follow-
up of the survivors was 72 months. During this period, 18 died of
their cancer and 13 of inter-current disease. On univariate survival
analysis (Table 3), tumour size (Po0.10), lymph node involvement
(Po0.0001), hormone receptor status (Po0.10), albumin
(Po0.01), Ki-67 (Po0.05), microvessel density CD34þ
(Po0.05), locoregional treatment (Po0.0001) and systemic treat-
ment (Pp0.01) were significantly associated with cancer-specific
survival. On multivariate analysis of these significant covariates,
albumin (HR 4.77, 95% CI 1.35–16.85, P¼0.015), locoregional
treatment (HR 3.64, 95% CI 1.04–12.72, P¼0.043) and systemic
treatment (HR 2.29, 95% CI 1.23–4.27, P¼0.009) were significant
independent predictors of cancer-specific survival. When albumin
was excluded from the multivariate analysis, only locoregional
treatment (HR 8.85, 95% CI 2.85–27.41, Po0.001) and systemic
treatment (HR 2.09, 95% CI 1.15–3.81, P¼0.016) were indepen-
dently associated with poorer cancer-specific survival.
On univariate survival analysis (Table 3), age (Po0.10), tumour
size (Po0.10), lymph node involvement (Po0.05), albumin
(Po0.01), microvessel density CD34þ (Po0.10), locoregional
treatment (Po0.01) and systemic treatment (Po0.10) were
significantly associated with overall survival. On multivariate
analysis of these significant covariates, age (HR 11.35, 95% CI
1.53–84.14, P¼0.018) albumin (HR 3.58, 95% CI 1.56–8.20,
P¼0.003), locoregional treatment (HR 2.67, 95% CI 1.24–5.72,
P¼0.012) and systemic treatment (HR 1.60, 95% CI 1.06–2.41,
Table 1 The clinicopathological characteristics of patients with invasive
primary operable breast cancer
Clinicopathological characteristics
Patients
(n¼168)
Age (p50/450 years) 32/136
Deprivation (1–2/3–5/6–7) 23/96/49
Type (ductal/lobular/special type) 142/20/6
Size (p20/21–50/450mm) 100/68/0
Grade (I/II/III) 28/87/52
Involved lymph node (0/1–3/43) 94/52/21
Hormonal receptor status (ER+ PR+/ER+ PR  or
unknown/ER  PR  or unknown)
54/79/35
White cell count (10
9 per l)
a 7.1 (3.4–13.5)
White cell count (o8.5/8.5–11/411 10
9 per l) 123/34/8
Albumin (gl
 1)
a 44 (37–50)
Albumin (443/p43gl
 1) 82/68
C-reactive protein (mgl
 1)
a p6( p6–66)
C-reactive protein (p10/410mgl
 1) 143/25
Ki-67 (tertiles 1, 2, 3)
b 6.2/15.5/37.2
CD34+ (p5/5–7/X7) 39/74/55
% Tumour-associated macrophages CD68+ (tertiles 1, 2, 3)
b 2.90/5.05/7.70
% Tumour T lymphocytes
CD4+ (tertiles 1, 2, 3)
b 0.03/0.30/1.32
CD8+ (tertiles 1, 2, 3)
b 0.27/0.73/2.23
Loco-regional treatment (mastectomy alone or conservation
surgery+radiotherapy/mastectomy+radiotherapy)
125/43
Systemic treatment (ER-based treatment) (hormonal/
hormonal+chemotherapy/chemotherapy/none)
80/53/29/5
ER¼oestrogen receptor; PR¼progesterone receptor.
aMedian (range).
bMedian.
Table 2 Inter-relationships between the clinicopathological characteristics in patients with invasive primary operable breast cancer
Involved
lymph node
(P-value)
Hormonal
receptor
status
(P-value)
Albumin
(P-value)
C-reactive
protein
(P-value)
Ki-67
(P-value)
CD34+
(P-value)
CD68+
(P-value)
CD4+
(P-value)
CD8+
(P-value)
Grade (I/II/III) 0.109 o0.001 0.216 0.653 o0.001 0.006 0.027 0.030 0.035
Involved lymph node (0/1–3/43) 0.843 0.150 0.554 0.504 0.106 0.079 0.360 0.633
Hormonal receptor status (ER+ PR+/ER+
PR  or unknown/ER  PR  or unknown)
0.047 0.804 o0.001 0.402 0.030 0.128 0.017
Albumin (443/p43gl
 1) 0.362 0.548 0.405 0.193 0.927 0.386
C-reactive protein (p10/410mgl
 1) 1.000 0.054 0.252 0.028 0.120
Ki-67 (tertiles 1, 2, 3) o0.001 0.001 o0.001 0.004
CD34+ (p5/5–7/X7) 0.002 0.048 0.256
% Tumour-associated macrophages
CD68+ (tertiles 1, 2, 3) 0.002 o0.001
% Tumour T lymphocytes
CD4+ (tertiles 1, 2, 3) o0.001
ER¼oestrogen receptor; PR¼progesterone receptor.
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sP¼0.025) were significant independent predictors of overall
survival. When albumin was excluded from the multivariate
analysis, only age (HR 5.27, 95% CI 1.24–22.35, P¼0.024) and
locoregional treatment (HR 3.44, 95% CI 1.66–7.12, Po0.001)
were independently associated with poorer overall survival.
When the tissue-based inflammatory factors alone, including
T lymphocytes, tumour-associated macrophages, microvessel
density and Ki-67 proliferation index, were considered in the
multivariate analysis, only increased tumour microvessel density
CD34þ (HR 2.42, 95% CI 1.16–5.03, P¼0.018) was independently
associated with poorer cancer-specific survival.
DISCUSSION
In this study, increased tumour grade and Ki-67 labelling index
were associated with increased infiltration by CD68þ tumour-
associated macrophages, CD4þ and CD8þ T lymphocytes and
increased tumour microvessel density in patients with primary
operable breast cancer. Furthermore, increased Ki-67 labelling
index and microvessel density were associated with poorer cancer-
specific survival. These results may be consistent with the concept
that there is an active immune response to poor tumour cell
differentiation that acts to increase the proliferative activity,
angiogenesis and dissemination of the tumour in these patients
(Pupa et al, 1996; Tsutsui et al, 2005; Lee et al, 2006; Lin and
Pollard, 2007). Alternatively, it may reflect a more passive
consequence of increased cytokine excretion from high-grade
proliferating tumours that attracts macrophages and T lymphocytes
and increases microvessel density.
Earlier studies have shown that tumour CD4þ T-lymphocyte
infiltration was associated with poor outcome, independent of
grade or stage, in patients with a variety of cancer including renal
and prostate cancer (Bromwich et al, 2003; McArdle et al, 2004).
However, in this study, the extent of tumour lymphocyte and
macrophage infiltration per se was not a significant prognostic
marker in determining disease outcome, consistent with earlier
studies (Griffith et al, 1990; Wintzer et al, 1991; Vgenopoulou et al,
2003).
Recently, Lee et al (2006) in 700 patients with stage 1 and 2
breast cancer and a median follow-up period of nearly 10 years
reported that, on simple staining with haematoxylin and eosin,
there was a significant relationship between the extent of both
macrophage and lymphocytic infiltration and cancer-specific
survival. Although, moderate or marked diffuse inflammation
was present in only 10% of tumours, only moderate or dense
tumour inflammatory infiltrates were associated with a better
prognosis in the subset of patients with grade 3 carcinomas.
The apparent discrepancies in the results of this study and those
of Lee et al (2006) and some other earlier studies may reflect
methodological differences, including the subsets of immune
cellular infiltrates examined and the way in which the inflamma-
tory infiltrates were assessed. In this study, the subsets of the
tumour cellular infiltrates were identified by immunohisto-
chemistry and the density was assessed using a point counting
technique. This approach provided a more objective assessment
and circumvents the problem of variation in distribution within an
individual tumour. In addition, some earlier studies have not
included the type of surgery and/or the adjuvant treatment
received in their survival analysis. However, the relatively limited
number of events and the relatively short follow-up period in our
study should also be taken into account.
In this study, also consistent with earlier works, increased
tumour Ki-67 labelling index (Veronese et al, 1993; Scholzen and
Gerdes, 2000; Trihia et al, 2003; Tsutsui et al, 2005) and micro-
vessel density (Hansen et al, 2000a,b; Uzzan et al, 2004; Tsutsui
et al, 2005) were significantly associated with poorer cancer-
specific survival. It was of interest that tumour-associated
macrophages, in addition to T lymphocytes, were subordinate to
increased tumour microvessel density and Ki-67 proliferation
Table 3 Univariate survival analysis of patients with invasive primary operable breast cancer
Cancer-specific Survival Overall Survival
Clinicopathological characteristics HR (95% CI) P-value HR (95% CI) P-value
Age (p50/450 years) 4.40 (0.59–33.05) 0.150 3.73 (0.89–15.62) 0.072
Deprivation (1–2/3–5/6–7)
a 1.15 (0.84–1.57) 0.371 1.22 (0.96–1.55) 0.111
Type (ductal/lobular/special type) 0.31 (0.05–2.06) 0.227 0.52 (0.18–1.51) 0.227
Size (p20/21–50/450mm) 2.45 (0.95–6.32) 0.064 1.91 (0.94–3.88) 0.073
Grade (I/II/III) 1.83 (0.88–3.81) 0.104 1.35 (0.78–2.32) 0.284
Involved lymph node (0/1–3/43) 3.13 (1.70–5.79) o0.001 1.67 (1.06–2.63) 0.026
Hormonal receptor status (ER+ PR+/ER+ PR  or unknown/ER  PR  or unknown) 1.81 (0.94–3.48) 0.076 1.48 (0.91–2.43) 0.116
White cell count (10
9 per l) 0.91 (0.71–1.17) 0.478 1.05 (0.88–1.26) 0.568
White cell count (o8.5/8.5–11/411 10
9 per l) 1.11 (0.50–2.49) 0.797 1.42 (0.81–2.49) 0.216
Albumin (gl
 1) 0.71 (0.60–0.85) o0.001 0.80 (0.70–0.91) o0.001
Albumin (443/p43gl
 1) 6.44 (1.85–22.41) 0.004 3.64 (1.61–8.22) 0.002
C-reactive protein (mgl
 1) 0.99 (0.92–1.06) 0.7353 0.98 (0.92–1.04) 0.517
C-reactive protein (p10/410mgl
 1) 0.69 (0.16–2.98) 0.6151 0.58 (0.18–1.92) 0.375
Ki-67 (tertiles 1, 2, 3) 1.97 (1.06–3.68) 0.033 1.34 (0.86–2.08) 0.193
CD34+ (p5/5–7/X7) 2.36 (1.15–4.85) 0.019 1.50 (0.91–2.45) 0.110
% Tumour-associated macrophages CD68+ (tertiles 1, 2, 3) 1.47 (0.80–2.69) 0.210 1.56 (0.99–2.47) 0.057
% Tumour T lymphocytes
CD4+ (tertiles 1, 2, 3) 0.97 (0.55–1.70) 0.913 1.11 (0.72–1.71) 0.629
CD8+ (tertiles 1, 2, 3) 0.92 (0.52–1.63) 0.770 1.16 (0.75–1.79) 0.514
Loco-regional treatment (mastectomy alone or conservation surgery+radiotherapy/
mastectomy+radiotherapy)
8.70 (3.09–24.44) o0.001 3.17 (1.56–6.41) 0.001
Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/
chemotherapy/none)
2.14 (1.27–3.60) 0.004 1.44 (0.95–2.16) 0.085
CI¼confidence interval; ER¼oestrogen receptor; HR¼hazard ratio; PR¼progesterone receptor.
aIndividual deprivation categories were used in the statistical analysis. HR 41
trend towards worse survival with each incremental change, HR o1 trend towards better survival with each incremental change.
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sindex, which were independently associated with poorer cancer-
specific survival. This would suggest that the reported prognostic
value of tumour-associated macrophages is probably due to their
positive involvement in tumour angiogenesis (Leek et al, 1996;
Tsutsui et al, 2005) and proliferation (Jonjic et al, 1998).
In agreement with our recent study (Al Murri et al, 2007), when
potentially curative locoregional and systemic treatment based on
hormonal receptor status were included in the multivariate
survival analysis, none of the potentially prognostic clinicopatho-
logical and tumour-based inflammatory factors were indepen-
dently significant. This probably reflects the close association
between the risk assessment and the treatment received and their
relative impact on relapse and survival. Adjuvant chemotherapy, in
addition to its direct cytotoxic effect on cancer cells, might also
attenuate surgery-stimulated tumour cell proliferation and angio-
genic surge possibly occurring at distant dormant or indolent
micrometastases (Retsky et al, 2004). Furthermore, adjuvant
chemoradiotherapy may be effective by virtue of its cellular
immune suppression and modification of specific host immune-
related mechanisms (Reizenstein et al, 1985; Stewart and Tsai,
1993).
The basis of the observation that albumin had independent
prognostic value is not clear but it may be that chronic illness,
reflected by a lower albumin (Goldwasser and Feldman, 1997), also
impacts on cancer survival. Alternatively, as a lower albumin
concentration was directly associated with hormone receptor-
negative tumours, an unfavourable prognostic sign, it may, in part,
reflect the biological functions of circulating albumin that include
binding and transporting of hormones and growth factors
(Margarson and Soni, 1998), inhibiting growth in the breast
tumour-cell cytosol (Soreide et al, 1991) and tumour proliferation
by modulating the activities of autocrine growth regulatory factors
(Laursen et al, 1990).
Other intracellular signalling systems may have important
functions in regulating cancer-cell survival and progression
pathways in patients with primary operable breast cancer. For
example, there is increasing evidence that nuclear factor-kB and its
associated pathways may be important in tumour progression in
patients with endocrine-resistant and hormone-negative tumours
(Zhou et al, 2005; Ciucci et al, 2006; Haffner et al, 2006).
In summary, the results of this show for the first time the inter-
relationships between the pre-operative systemic inflammatory
response, tumour-based factors and outcome in patients with
primary operable breast cancer. The host inflammatory responses
appear to be closely related to poor tumour proliferation and
differentiation and malignant disease progression in primary
invasive early-staged disease. Only pre-operative albumin con-
centration, locoregional and systemic treatments were independent
predictors of cancer-specific survival.
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